Page last updated: 2024-11-01

nimodipine and Polyneuropathies

nimodipine has been researched along with Polyneuropathies in 2 studies

Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.

Polyneuropathies: Diseases of multiple peripheral nerves simultaneously. Polyneuropathies usually are characterized by symmetrical, bilateral distal motor and sensory impairment with a graded increase in severity distally. The pathological processes affecting peripheral nerves include degeneration of the axon, myelin or both. The various forms of polyneuropathy are categorized by the type of nerve affected (e.g., sensory, motor, or autonomic), by the distribution of nerve injury (e.g., distal vs. proximal), by nerve component primarily affected (e.g., demyelinating vs. axonal), by etiology, or by pattern of inheritance.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fadhlillah, F1
Patil, S1
Cai, X1
Bhattacharyya, S1
Plitt, A1
Raibagkar, P1
LaBuzetta, JN1
Schleicher, SM1
Munshi, NC1
Klein, JP1

Other Studies

2 other studies available for nimodipine and Polyneuropathies

ArticleYear
Pharmacological and mechanical management of calcium channel blocker toxicity.
    BMJ case reports, 2018, Aug-27, Volume: 2018

    Topics: Acute Kidney Injury; Calcium Channel Blockers; Combined Modality Therapy; Drug Overdose; Extracorpor

2018
Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Jan-10, Volume: 34, Issue:2

    Topics: Anticonvulsants; Antihypertensive Agents; Antineoplastic Agents; Biomarkers, Tumor; Bortezomib; Brai

2016